Prometic recently announced a financial agreement and partnership with Shenzhen Royal Asset Management (SRAM) to develop, manufacture, and commercialize several of its anti-fibrotic products in China, including PBI-4050 for idiopathic pulmonary fibrosis (IPF). PBI-4050 is an anti-fibrotic oral drug, which has demonstrated positive results in a Phase 2 study (NCT02538536) in patients…
Prometic to Advance IPF and Other Anti-fibrotic Therapies in Clinical Testing via Partnership in China
This video from The Mighty shares some of the things a person living with a chronic illness might want to carry around with them on a daily basis. MORE: 7 Airway Clearance Techniques The survival pack contains some of the essentials needed to ensure you’re not caught out when going…
By definition, I always understood naivety to mean inexperience, lack of understanding or wisdom about  a particular topic. Such things could include naivety about the topic of a difficult discussion, or an unrealistic expectation of a timeline for something to happen. In relation to illness, this definition…
The Chicago-based Pulmonary Fibrosis Foundation (PFF) will hold its inaugural PFF Walk on Sept. 9 to mark PF Awareness Month. More than 400 individuals and 80 teams from across the United States have registered for the event at Chicago’s Lincoln Park. In addition, “virtual walks” will take place throughout the nation…
In this video from Demystifying Medicine, learn more about the difference between pulmonary fibrosis (PF) and idiopathic pulmonary fibrosis (IPF) and hear the answers to other frequently asked questions from patients living with the disease. MORE: Top five recommended reads for pulmonary fibrosis. The animated film tackles…
I recently learned of a competition for innovators and entrepreneurs in the tech, healthcare, and scientific research communities to help those living with pulmonary fibrosis. It’s called the $1 million IPF Catalyst Challenge and it is awarding a million-dollar prize for quality-of-life solutions to help patients and…
While doctors are sometimes able to identify the causes which led to the development of pulmonary fibrosis (PF), there are many instances where the cause can not be determined, making it a case of idiopathic pulmonary fibrosis (IPF). MORE: Study links biology of aging and IPF, opens new paths for possible therapies…
As a patient living with idiopathic pulmonary fibrosis (IPF), I am extremely grateful to the researchers, doctors, health advocates, and other professionals dedicated to enhancing the quality of life for those of us enduring this horrible disease. I am thankful that research is under way to further…
GLPG1690, an investigational therapy developed by Galapagos to treat idiopathic pulmonary fibrosis (IPF), prevented further lung decline in a Phase 2a trial, allowing the Belgian pharmaceutical firm to rapidly move forward with the clinical development of this therapy. The trial, called FLORA (NCT02738801), involved randomly assigning 17 IPF patients treatment with GLPG1690 and…
Key leaders in the idiopathic pulmonary fibrosis therapy development industry, representing large pharma and biotech firms, academia  and contract research organizations, will gather at the inaugural IPF Summit in Boston, Aug. 21-23. This forum will cover the latest in IPF drug development, from late discovery to early clinical studies.
